SRPK1 and neoplasm: However, SRPK1 inhibition or downregulation has also been linked with cis/carboplatin chemotherapy resistance, highlighting that the therapeutic benefit of SRPK inhibition is likely tumour‐type and/or isoform dependent [308, 309, 310].